Recurrent Thyroid Gland Carcinoma Clinical Trial
Official title:
A Phase II Study of GW 786034 (Pazopanib) in Advanced Thyroid Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with advanced thyroid cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor.
PRIMARY OBJECTIVE:
I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a
therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid
cancers.
CORRELATIVE OBJECTIVES:
I. Assessment of the impact of therapy with GW786034 on serum/plasma vascular endothelial
growth factor (VEGF) levels.
II. To explore the potential relationship between changes in thyroglobulin levels and tumor
response in patients with advanced differentiated thyroid cancer known to be thyroglobulin
antibody negative.
OUTLINE:
Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28. Cycles
repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for up to 3
years after registration.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
| Completed |
NCT01709435 -
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT01811212 -
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02393690 -
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
| Recruiting |
NCT04759911 -
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
|
Phase 2 | |
| Completed |
NCT00559949 -
AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
|
Phase 2 | |
| Active, not recruiting |
NCT00381641 -
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
|
Phase 2 | |
| Recruiting |
NCT05003856 -
Radiofrequency Ablation for the Treatment of Benign or Low Risk Thyroid Nodule
|
N/A | |
| Completed |
NCT00729157 -
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
Phase 2 | |
| Active, not recruiting |
NCT02465060 -
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT02152995 -
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
|
Phase 2 |